EC Number |
Inhibitors |
Structure |
---|
3.4.21.108 | 5-[5-(2-nitrophenyl)furfuryliodine]1,3-diphenyl-2-thiobarbituric acid |
UCF-101 |
|
3.4.21.108 | antisense HtrA2 |
significantly inhibits IFN/all-trans retinoic acid-induced degradation of X-linked inhibitor of apoptosis protein |
|
3.4.21.108 | diisopropylfluorophosphate |
complete inhibition at 4 mM |
|
3.4.21.108 | DPMFKL |
peptide DPMFKL which inhibits protease HtrA1, EC 3.4.21.107, is not inhibitory to enzyme HtrA2 up to 0.1 mM. For protease HtrA2 mutant lacking the regulatory domain, the peptide acts as a competitive inhibitor, displaying a IC50 value of 0.33 mM |
|
3.4.21.108 | DSRIWWV |
- |
|
3.4.21.108 | etoposide |
ratio of C161M/APP decreases 66% during 0.0040 mM etoposide-induced apoptosis compared with the non-apoptotic condition |
|
3.4.21.108 | FGRWV |
- |
|
3.4.21.108 | HtrA2 siRNA |
- |
|
3.4.21.108 | more |
ucf-101 fails to exert any additional protective effect in transfected cells |
|
3.4.21.108 | more |
Akt abrogates HtrA2/Omi pro-apoptotic function through phosphorylation of serine 212 in cytoplasm and inhibition of its release from the mitochondria in response to cisplatin treatment. Caspase inhibitor z-VAD-FMK reduces the mature HtrA2/Omi-induced cell death by ca. 45% |
|